Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the ...
Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback